Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci.

Blood
L J RushC Plass

Abstract

Aberrant DNA methylation is believed to be important in tumorigenesis by causing either transcriptional inactivation of genes or chromosomal instability. Several laboratories have identified promoter hypermethylation of tumor suppressor genes in acute myeloid leukemia (AML). However, these studies do not provide a global assessment of overall methylation changes and do not allow the identification of novel methylated sequences. Previously, nonrandom CpG island methylation was reported in 17 adult de novo AML diagnostic samples when compared with the corresponding remission samples by means of restriction landmark genomic scanning (RLGS). That study has been expanded on by an analysis of a larger set of CpG islands (1740 vs 1184), which now provides details of 33 cloned methylated loci, including 21 known genes or expressed sequence tags. Five of these cloned loci appear to be methylated only in AML and not in the 6 solid tumors studied in this study (more than 98 samples analyzed). Chromosomal location was available for 30 of the 33 loci, and 5 of these 30 (17%) are localized to chromosome 11, suggesting a trend toward overrepresentation of methylation events on this chromosome. These results provide evidence for widespread abe...Continue Reading

Citations

Jan 18, 2006·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Romulo Martin BrenaChristoph Plass
May 16, 2007·Annals of Biomedical Engineering·Eva K Lee
Jul 27, 2002·Cancer Letters·Laura J Rush, Christoph Plass
Aug 23, 2002·Seminars in Cancer Biology·John R Melki, Susan J Clark
Oct 31, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Giuseppe LeoneMichael Lübbert
May 7, 2005·Nature Biotechnology·George L Gabor Miklos
Feb 26, 2005·Nature Genetics·Joseph F Costello
Oct 2, 2002·Nature Genetics·Giuseppe ZardoJoseph F Costello
Aug 16, 2002·British Journal of Haematology·Louise K Jones, Vaskar Saha
Feb 15, 2002·The Journal of Biological Chemistry·Sarmila MajumderSamson T Jacob
Mar 25, 2008·Therapeutics and Clinical Risk Management·Kavita Raj, Ghulam J Mufti
Jun 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Chibo HongJoseph F Costello
Oct 21, 2004·American Journal of Hematology·Cumhur G EkmekciKishor Bhatia
May 27, 2011·Cancer Treatment Reviews·Till Schoofs, Carsten Müller-Tidow
May 24, 2011·Cancer Treatment Reviews·Anna R Poetsch, Christoph Plass
Aug 12, 2008·Seminars in Oncology·Christoph PlassGuido Marcucci
Nov 18, 2003·British Journal of Haematology·Marc TischkowitzHans Joenje
May 29, 2008·Genes, Chromosomes & Cancer·Manu GuptaBryan D Young
Oct 8, 2005·Seminars in Oncology·Minoru Toyota, Jean-Pierre J Issa
Mar 11, 2005·Expert Opinion on Therapeutic Targets·Björn HackansonMichael Lübbert
Feb 5, 2002·Molecular Genetics and Metabolism·Michael C Frühwald, Christoph Plass
Aug 14, 2002·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Samuel W FrenchMichael A Teitell
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Remco van DoornCornelis P Tensen
Oct 7, 2003·Oncogene·Rainer Claus, Michael Lübbert
Mar 16, 2002·European Journal of Human Genetics : EJHG·Christoph Plass, Paul D Soloway
Aug 3, 2002·Oncogene·Dominic J Smiraglia, Christoph Plass
Sep 26, 2007·Human Molecular Genetics·Romulo M Brena, Joseph F Costello
Sep 10, 2017·Journal of Cellular Physiology·Narges SoozangarNasser Samadi
Nov 23, 2013·Journal of Neuro-oncology·Rebekka UnlandMichael C Frühwald
Sep 24, 2010·Cancer Control : Journal of the Moffitt Cancer Center·Jong Y Park
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Clara D BloomfieldMichael A Caligiuri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.